This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?
by Zacks Equity Research
On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Agenus
by Zacks Equity Research
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
What Makes Agenus (AGEN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AGEN) Outperforming Other Medical Stocks This Year?
Agenus' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Agenus.
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGEN) Outperforming Other Medical Stocks This Year?
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Protalix Submits BLA for Fabry Disease Candidate PRX-102
by Zacks Equity Research
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Mersana Stock Spikes on Interim Data on Cancer Candidate
by Zacks Equity Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
Ironwood to Halt MD-7246 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
Agenus (AGEN): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Agenus (AGEN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 11.43% and 22.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?